Proteomic Based Drug Discovery Summit 2025

Proteomics offers huge advantages for the discovery and pre-clinical development of small molecule drugs and their translation into robust clinical candidates. Just this year, Sanofi has dedicated $700M to Belharra Therapeutics to develop a proteomics platform and Galapagos has partnered with Bridgene Bio to combine chemoproteomics with computational tools. This is the time to harness the power of proteomics to accelerate your drug development process and de-risk your pipeline. The Inaugural Proteomics-Based Drug Discovery Summit comes to Boston as the first industry dedicated event to help solve bottlenecks across your drug development chain including hit screening, target validation, hit to lead progression and in vivo translation to leverage the power of the proteome and drug the “undruggable”. In 2025, make sure you join experts where you will hear exclusive data revealed, towards supercharging your experiments for screening compound libraries, unravelling the mechanism of action, deconvoluting protein-protein interactions and determining drug potency to gear your proteomics platforms for faster development of more effective drugs to change patient lives.

Event Links

Website: https://go.evvnt.com/2674449-0

Tickets: https://go.evvnt.com/2674449-2

Brochure: https://go.evvnt.com/2674449-3

Read More

View Less